PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
09 mai 2019 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
Completed underwritten public offering of common stock that raised $46.2 million in net proceeds Received FDA Breakthrough Therapy designation for PB2452 Results from Phase 1 clinical trial of...
PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
02 mai 2019 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 avr. 2019 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Pricing of Public Offering of Common Stock
11 avr. 2019 21h19 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., and SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Proposed Public Offering of Common Stock
09 avr. 2019 16h45 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
09 avr. 2019 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
08 avr. 2019 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
26 mars 2019 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session Initiated Phase 2b trial...
PhaseBio Announces Term Loan of up to $15 Million
25 mars 2019 16h30 HE
|
PhaseBio Pharmaceuticals, Inc.
Entered into term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund to borrow up to $15 million Funds will be used to advance clinical development of PB2452, a reversal...
PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
19 mars 2019 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...